NCT00658411TERMINATEDanonymous

A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndromes or Acute Leukemia and Iron Overload

Sponsor

Source record

Dana-Farber Cancer Institute

Phase

Source record

Not Applicable (Pilot Study)

Modality

AI-normalized

small molecule

Target

AI-normalized

Deferoxamine, an iron chelator, targets excess iron in patients with iron overload, particularly in the context of myeloablative allogeneic stem cell transplantation.

Indication / condition

AI-normalized

Acute Myeloid Leukemia

Intervention

Source record

deferoxamine

Source & freshness

Source record

NCT ID

NCT00658411

Original source

ClinicalTrials.gov

Source last updated

Apr 09, 2013

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00658411

Title

A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndromes or Acute Leukemia and Iron Overload

Sponsor

Dana-Farber Cancer Institute

Status

TERMINATED

Phase

Not Applicable (Pilot Study)

Condition raw

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome

Condition normalized

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Deferoxamine, an iron chelator, targets excess iron in patients with iron overload, particularly in the context of myeloablative allogeneic stem cell transplantation.

Target normalized

Deferoxamine, an iron chelator, targets excess iron in patients with iron overload, particularly in the context of myeloablative allogeneic stem cell transplantation.

Interventions

deferoxamine

Public preview

Source record

The pilot study sponsored by Dana-Farber Cancer Institute aimed to evaluate the safety and feasibility of deferoxamine in patients with myelodysplastic syndromes or acute leukemia undergoing stem cell transplantation. The study was terminated due to slow patient accrual, indicating potential challenges in recruitment for future studies. The market for iron chelation therapy is significant, particularly in hematological malignancies, but the competitive landscape includes established therapies and emerging novel agents. The limited patient enrollment raises concerns about the viability of further development without robust data supporting efficacy and safety.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndromes or Acute Leukemia and Iron Overload

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00658411

Status

TERMINATED

Phase

Not Applicable (Pilot Study)

Sponsor

Dana-Farber Cancer Institute

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 09, 2013

Internal syncJun 12, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00658411

Indication

Acute Myeloid Leukemia

Modality

small molecule

Target

Deferoxamine, an iron chelator, targets excess iron in patients with iron overload, particularly in the context of myeloablative allogeneic stem cell transplantation.

Intervention

deferoxamine

Source record